Kornimate/medical-research-clean huggingface dataset:
recurrence patterns and cost-effectiveness of surgical approaches in early-stage hepatocellular carcinoma

Conditions: HCC - Hepatocellular Carcinoma

Summary: this study aims to investigate the recurrence patterns and cost-effectiveness of robotic-assisted, laparoscopic, and open liver resections in patients with early-stage (bclc 0/a) hepatocellular carcinoma. by analyzing data from 3000 patients across 27 centers, the research evaluates recurrence-free survival, overall survival, and long-term economic impacts using metrics such as quality-adjusted life years (qalys) and incremental cost-effectiveness ratios (icers). findings will provide insights into optimal surgical approaches to improve patient outcomes and healthcare resource utilization.


Eligibility criteria:
inclusion criteria: * (1) hcc diagnosis confirmed by two independent radiologists using contrast-enhanced computed tomography (ct) and/or magnetic resonance imaging (mri) combined with postoperative pathology; (2) bclc stage 0 or a; and (3) curative liver resection exclusion criteria: * (1) concurrent malignancies in other organs; (2) diagnosis of combined hepatocellular-cholangiocarcinoma; (3) prior neoadjuvant or adjuvant treatment before liver resection; (4) recurrent hcc; (5) ruptured hcc; and (6) incomplete follow-up or missing data.
ng101m adjuvant therapy in glioblastoma patients

Conditions: Glioblastoma Multiforme

Summary: the purpose of this clinical trial is to evaluate the addition of ng101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. all subjects will receive ng101m capsules along with the standard treatment of temozolomide and radiation.

glioblastoma multiforme (gbm) is the most lethal form of malignant brain cancer, with about 12,000 new cases diagnosed each in the the united states. the current standard treatment consists of maximal, safe resection, followed by radiation therapy of 60 gray (gy) with concomitant oral temozolomide (tmz) for 6 weeks, then continue with six cycles of high-dose temozolomide. the median survival rate for newly diagnosed gbm patients is 14.6 months with a 2-year overall survival (os) rate of 27.2%. this clinical trial evaluates the 2-year os of oral ng101m as an adjuvant therapy to chemoradiotherapy in newly diagnosed gbm subjects.

Eligibility criteria:
inclusion criteria: * male or female subjects ≥ 18 years of age * must be newly diagnosed with gbm * primary treatment must consist of a chemoradiation therapy (crt) regimen * hemoglobin \> 9 g/dl * white blood count 3,600 - 11,000/mm3 * absolute neutrophil count (anc) ≥ 1,500/mm3 * absolute lymphocyte count (alc) ≥ 1,000/mm3 * platelet count 100,000/mm3 * bun ≤ 1.5 times upper limit of normal * creatinine clearance rate \> 40 ml/min * alt ≤ 3 times upper limit of normal * ast ≤ 3 times upper limit of normal * alkaline phosphatase ≤ 3 times upper limit of normal * total bilirubin ≤ 2.0 mg/dl * karnofsky performance status ≥ 70 * must not be on any other alternative therapies * not pregnant exclusion criteria: * known hypersensitivity to meloxicam, famotidine, and/or caffeine or any of their derivatives or components * known allergy to vitamin a, vitamin d3, and/or l-citrulline * pregnant women * breastfeeding women * corticosteroid therapy that cannot be tapered down to a dose of 1 - 2 mg/day of dexamethasone or its equivalent * history of immunodeficiency diseases or autoimmune diseases * history of peptic ulcer disease or gastrointestinal perforation
new technique as an additional diagnostic tool for women undergoing neoadjuvant therapy for breast cancer

Conditions: Breast Cancer

Summary: molecular breast imaging is a highly promising novel methodology for breast cancer detection. preliminary patient studies with our dual-detector system indicate that this system is capable of reliably detecting very small (5-10 mm) malignant lesions in the breast. besides the usefulness of molecular breast imaging for tumor detection, we speculate that tumor uptake and washout may be predictors to response to neoadjuvant therapy for patients with the diagnosis of breast cancer. we propose that in patients with breast cancer who undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy that molecular breast imaging is an accurate test for assessing response rate to neoadjuvant therapy.

adjuvant therapy after surgery for breast cancer has provided significant benefits to patients at risk for relapse. however, the success of therapy for each individual patient will often take years to reveal. preoperative (neoadjuvant) medical therapy is very potent as an initial treatment for inoperable and large operable breast cancers. tumor regression can be achieved in the great majority of patients and downstaging frequently reduces the need for mastectomy and it has become clear that pathologic complete response is a good prognostic marker. data from current trials suggest that survival is at least as good with preoperative as with postoperative neoadjuvant therapies (1). with this observation preoperative medical therapy has the advantage over post-operative neoadjuvant therapy that it can be used as a short term surrogate marker for long-term outcome. with this translational approach, the therapy for each patient can be more targeted and individualized leading to higher success rates; and further, new therapies for early breast cancer can be assessed much more quickly than is currently possible through protracted trials of neoadjuvant therapy (2). this approach is therefore being increasingly utilized in patients with lower stage breast cancers.

Eligibility criteria:
inclusion criteria: * women age 18 - 90 * women with breast cancer scheduled to undergo neoadjuvant chemotherapy therapy or neoadjuvant hormone therapy * women who have undergone any breast imaging procedure, and in whom a repeat imaging procedure is planned prior to definite surgery exclusion criteria: * pregnant or lactating * unable to understand or sign a consent form * physically unable to sit upright and still for 40 minutes

Keywords: mbi breast cancer neoadjuvant therapy molecular breast imaging
dynamic and test-retest whole body [18f]fes pet imaging in patients with metastatic er+ breast cancer

Conditions: Breast Cancer

Summary: 16a-18f-fluoro-17b-estradiol (\[18f\]fes) is radioactive labeled estradiol, developed for in vivo visualization of the estrogen receptor (er) using positron emission tomography (pet). to date, \[18f\]fes pet has been mainly explored as a diagnostic imaging tool to assess er expression, thereby identifying locations of disease and their potential sensitivity to endocrine therapy, respectively. the primary aim of this project is to extend the application of \[18f\]fes pet as a baseline diagnostic imaging biomarker for er expression to use it as an (early) treatment response marker. however, for such an application, visual assessment alone may not be sufficient and a more rigorous quantitative image analysis is needed. therefore, in this project we shall first derive the optimal pharmacokinetic model for full quantitative analysis of \[18f\]fes uptake and, subsequently, we shall assess the validity of simplified, clinically feasible, quantitative parameters of \[18f\]fes uptake in 5 patients with metastatic estrogen receptor positive (er+) breast cancer (part a). in addition, the repeatability of these simplified parameters will then be investigated in another 10 patients (part b).


Eligibility criteria:
inclusion criteria: * histologically proven metastatic er+ (\>10% positive stained cells using immunohistochemistry) breast cancer on the latest biopsy * postmenopausal females aged 18 years or older at screening. postmenopausal status is defined as one of the following: 1. age ≥60 years 2. age \ 12 months in the absence of interfering hormonal therapies (such as lh-rh agonists and er-antagonists) 3. patient age \<60 years using lh-rh agonists should continue lh- rh-agonists until after the pet procedures 4. previous bilateral oophorectomy or medically confirmed ovarian failure * \[18f\]fdg pet, ct and/or a bone scan should be performed as part of routine clinical staging (≤4 weeks prior to screening) * patients should have metastases in the scanning field of view, all located outside of the liver * eastern cooperative oncology group performance status (ecog ps) of 0-2 * estimated glomerular filtration rate (egfr) ≥30 ml/min * written and signed informed consent exclusion criteria: * history with another cancer within the last 5 years, except cancer treated with curative intent and no evidence of disease as judged by the treating physician * use of selective estrogen receptor modulators (serms) or downregulators (serds) for current breast cancer such as tamoxifen/fulvestrant (≤5 weeks prior to screening) or investigational drug therapy * pregnancy or lactating women * any medical, psychological or social condition that may interfere with the subject's safety and participation in the study, will lead to exclusion from this study
pilot study for feasibility of using an oral appliance for decreasing snoring

Conditions: Snoring

Summary: this research study proposes to determine how well tolerated and effective lower and upper oral dental devices are at reducing snoring. the device is designed to move the genioglossus muscle forward, with interior attachment to maintain forward placement of of he tongue on the bottom of the mouth.

this study proposed to determine if the use of an oral device which causes forward positioning of the tongue will decrease the intensity and frequency of snoring as measured by the snorelab phone app, evaluate the level of snoring as measured by the bed partner, evaluate tolerance and comfort of the device and evaluate the quality of sleep of the subject by the bed partner. subjects will sleep at home using the snorelab app to record snoring for five nights and fill out the snore outcomes survey. they will then utilize the lower dental device for five nights recording their snoring. at the end of the five nights of using the lower dental device, the subjects will fill out the comfort and difficulties form with the bed partner completing the snore outcomes survey. if the lower device is tolerated, the process is repeated with the upper device added to the lower device.

Eligibility criteria:
inclusion criteria: 1. . able to provide informed consent 2. age 18 or older 3. self-report of snoring problems 4. has a bed partner that is willing and able to consent as well as answer questions related to partner's snoring both with and without oral device- exclusion criteria: 1. missing teeth. 2. respiratory disorders requiring treatment including asthma, copd 3. poor dental health including gum disease or loose teeth 4. dental implants placed within the last three months 5. temporomandibular joint dysfunction 6. presence of mouth or jaw pain 7. bruxism (teeth grinding) 8. full dentures 9. no bed partner 10. braces 11. diagnosed with obstructive or central sleep apnea, sleep apnea 12. uncontrolled rls 13. ongoing or prior use of a dental device 14. noise in bedroom i.e., fan, bed partner snoring 15. other medical or sleep issues which will interfere with the device per pi discretion 16. does not have a smart phone 17. other medical condition that pi believes will make the patient ineligible for participation
coraline - correlation between physiological and clinical variables and failure of non-invasive respiratory support in patients with acute respiratory failure

Conditions: Acute Respiratory Failure

Summary: this observational study aims to evaluate the relationship between clinical and physiological variables and the failure of non-invasive respiratory support (nirs), including high-flow nasal oxygen (hfno) and non-invasive ventilation (niv), in patients with acute respiratory failure (arf), both hypoxemic and/or hypercapnic. the study includes both retrospective and prospective components. retrospective data will be collected from patient charts, while prospective data will be collected at defined time points during clinical care. the primary outcome is nirs failure, defined as the need for orotracheal intubation. secondary outcomes include in-hospital and 90-day mortality, icu and hospital length of stay, and duration of non-invasive and invasive support.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * hospitalization in the respiratory medicine unit at aou policlinico di modena * acute respiratory failure (hypoxemic and/or hypercapnic) with pao₂/fio₂ \< 300 mmhg * undergoing treatment with hfno or niv exclusion criteria: * immediate need for invasive ventilation upon admission * known neuromuscular disease * pregnancy * lack of informed consent

Keywords: acute respiratory failure high flow nasal cannula non-invasive ventilation inspiratory effort
effects of diaphragmatic manual therapy in chronic low back pain

Conditions: Low Back Pain

Summary: this study is a double-blind randomized clinical trial with two arms which aims to study the effects of diaphragmatic treatment in patients with nonspecific low back pain. low back pain has a great importance in today's society, and it is therefore important to develop an effective treatment for this condition. people with chronic nonspecific low back pain, can present respiratory disorders and get anxiety states, affecting mainly the diaphragm muscle. therefore, given its direct anatomic relationship, the diaphragm may be part of the development of chronic low back pain. although clinical practice guidelines for chronic low back pain have been developed, it hasn't been explored before a physiotherapy treatment especially aimed at a diaphragmatic treatment. a double-blind randomized clinical trial with two arms will be used for this purpose, 64 patients with nonspecific low back pain referred from different hospitals of castellón will be randomized into two groups: * diaphragmatic intervention with osteopathic manual therapy treatment (d). * diaphragmatic intervention with placebo treatment group (p). an osteopathic manual therapy protocol for the treatment of back pain including techniques for the diaphragm muscle will be applied to the patients in group d, in a total of 5 sessions. for patients in group p, the same protocol will be performed on the diaphragm but with placebo treatment techniques. the study focuses on the analysis of the following variables: scores on the questionnaires: * pain: mcgill pain questionnaire and vas (visual analogical scale ). * fear avoidance: (fabq) * disability: oswestry disability index and roland-morris * anxiety: hads: (hospital anxiety and depression scale) * catastropizing: pcs (pain catastropizing scale) * satisfaction with treatment (escala de satisfacción con el tratamiento) the results of these pre-intervention and post-intervention variables will be compared between the two groups in the first session, in the fourth session and in the first and third month after the first intervention. the vas score will also be assessed in the second and third session.


Eligibility criteria:
inclusion criteria: * low back pain for more than 3 months exclusion criteria: * vertebra fracture * systemic disease * spinal surgery * degenerative articular disease * acute soft tissue inflammation * radiculopathy * structural spine deformities * pregnancy * mental disease * dermatologic disease * rejection to manual contact

Keywords: diaphragm osteopathic treatment myofascial release
database registry of the intermountain heart collaborative study

Conditions: Coronary Artery Disease; Electrophysiology; Cardiovascular Disease

Summary: the purpose of the registry is to collect and analyze clinical and laboratory data and tissue samples from patients who are diagnosed with any type of heart disease and to collect the same information and samples from healthy controls in participating intermountain healthcare facilities.

this is a registry (database) project; there are no investigational treatments, drug or procedures associated with participation in registry activities. this project is an organized data gathering and storing (database) endeavor with specific focus on the precursors, modifiers, biological, and genetic parameters of heart disease and related medical conditions. data collection will not immediately influence the course of treatment for any patient.sample testing and data utilization for basic science, clinical, and epidemiologic and publication projects can be initiated using the databank. the registry will enable researchers to determine best medical practices for predicting, preventing, and treating heart disease. the registry will: 1) develop standard methods to collect data and specimens which will be used for research to characterize patients diagnosed with heart disease as well as healthy controls and to assess differences in demographics and patient outcomes in both populations; 2) collect, process, and store patients' clinical data and tissue/blood samples; 3) analyze data collected; 4) use these resources to identify genes, genetic polymorphisms, genetic mutations, clinical methods and procedures, and/or biomarkers that predict, prevent, or treat heart disease and/or are associated correlate with lifestyle or disease outcomes; 5) publish and disseminate results.

Eligibility criteria:
inclusion criteria: 1. the patient (male or non-pregnant female) must be \> 18 years of age. 2. the patient or legally authorized representative must sign a written informed consent, prior to the procedure, using a form that is approved by the local institutional review board. exclusion criteria: 1. neither patient nor patient representative understands spoken english. 2. neither patient nor the patient's personal representative is willing to give written consent for participation. 3. healthy control patients must sign their own consent document.

Keywords: registry cardiac catheterization laboratory coronary heart disease cardiovascular disease
fmri neurofeedback with matter neuroscience app

Conditions: Depression Mild; Depression; Depression Moderate

Summary: study will utilize an app, matter neuroscience, designed to help users with depression understand positive emotions and the neurotransmitters that create them. we hope to learn the safety and efficacy of neurofeedback for treating depression and lay the groundwork for a pivotal clinical trial.


Eligibility criteria:
inclusion criteria: 1. male or female, between the ages of 18 and 80 at the time of screening. 2. able to read, understand, and provide written, dated informed consent prior to screening. proficiency in english sufficient to complete questionnaires / follow instructions during fmri. stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information. 3. must possess an iphone with ios 17 or higher. 4. single-ssri-resistant depressive disorder patients with a madrs scale between 20-34 exclusion criteria: 1. contraindication to mri (ferromagnetic metal in their body) 2. claustrophobia 3. severe major depressive disorder (mdd) 4. madrs scale of \>34 5. treatment-resistant depression (trd) from 3 or more treatments. 6. any other condition deemed by the pd to interfere with the study or increase risk to the participant
epigenetic biomarkers for alzheimer's disease

Conditions: Alzheimer Disease

Summary: alzheimer's disease (ad) is a neurodegenerative disorder with no know cure. the pathogenesis of late onset ad (load) is complex and multifactorial in nature, with multiple susceptibility genes and environmental factors at interplay. the objective of this study is to improve our understanding of the risk factors of load by conducting an epigenome wide study within patients of load contrasted against their cognitively normal siblings.


Eligibility criteria:
inclusion criteria: * sufficient cantonese competency for cognitive test * written informed consent given * have at least one gender-matched cognitively normal sibling exclusion criteria: * subjects who refuse blood taking procedure * do not have a reliable family/caregiver informant (personal contact at least once a month)
satisfaction with phosphodiesterase 5 inhibitors treatment in patients with cardiovascular risk

Conditions: Erectile Dysfunction

Summary: evaluate satisfaction in people treated with ipde5 inhibitors over time

12 first patients that are eligible

Eligibility criteria:
inclusion criteria: * cv risk factors * male above 18 exclusion criteria: * non-informed consent

Keywords: satisfaction
a study evaluating safety and efficacy of venetoclax in combination with azacitidine versus standard of care after allogeneic stem cell transplantation (sct) in participants with acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia (AML); Cancer

Summary: the main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve overall survival (os) in acute myeloid leukemia (aml) participants compared to best supportive care (bsc) when given as maintenance therapy following allogeneic stem cell transplantation (sct). this study will have 2 parts: part 1 (dose confirmation), which may include participants who are greater than or equal to 18 years old; part 2 (randomization) which may include participants who are greater than or equal to 12 years old. during part 1, recommended phase 3 dose of venetoclax in combination with azacitidine will be determined and during part 2, the efficacy and safety of venetoclax with azacitidine (part 2 arm a) will be compared with bsc (part 2 arm b).


Eligibility criteria:
inclusion criteria: * participants must be at least 18 years old for part 1 and, at least 12 years old for part 2. * participant must be diagnosed with acute myeloid leukemia (aml) by world health organization (who) criteria (2017) and either be planning for allogeneic stem cell transplantation or have received allogeneic stem cell transplantation within the past 60 days. * blast percentage in bone marrow before transplant must be \< 10%. * blast count in peripheral blood must be "0" and blast percentage in bone marrow must be \< 5% after transplant. * participant meet adequate renal, hepatic and hematologic criteria as described in the protocol. * participants \>= 17 years old must have a karnofsky performance scale (kps) score \> 50 and participants between 12 to 16 years old must have a lansky play performance scale score \> 40. exclusion criteria: * history of disease progression during prior treatment with venetoclax. * history of any other malignancy within 2 years prior to study entry, except for: adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; myelodysplastic syndrome, myeloproliferative neoplasm (only allowed if it transformed to aml and aml should be the indication for marrow transplantation). * participant has known infection with hiv or history of being positive for hepatitis b virus (hbv) or hepatitis c virus (hcv) infection. * presence of clinical or laboratory symptoms/signs of extramedullary myeloid malignancy.

Keywords: acute myeloid leukemia (aml) venetoclax azacitidine stem cell transplantation (sct) best support care (bsc) cancer